Verastem, Inc. Investing Cash Flow
Verastem, Inc. (VSTM) reported Investing Cash Flow of $235.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Verastem, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $16.25M.
- Verastem, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$16.02M.
- Verastem, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$1.34M.
- Verastem, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Verastem, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$9.62M, a 116.05% decline from fiscal 2024.
- Verastem, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $59.97M.
- Verastem, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$44.45M, a 167.16% decline from fiscal 2022.
- Verastem, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $66.19M, a 75974.71% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $16.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $235.00K 10-Q · filed 2026-08-06 | -$1.11M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$16.02M 10-Q · filed 2026-05-07 | -$17.36M derived: sum of 2 quarters · filed 2026-05-07 | |||
| 2025-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$9.62M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | -$8.28M 10-Q · filed 2025-11-04 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $28.99M derived: sum of 3 quarters · filed 2026-03-04 | $59.97M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $28.99M derived: sum of 2 quarters · filed 2025-11-04 | $59.97M 10-Q · filed 2025-11-04 | $72.41M derived: sum of 4 quarters · filed 2026-03-04 | |
| 2024-06-30 | $28.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $59.97M 10-Q · filed 2025-08-07 | $72.41M derived: sum of 3 quarters · filed 2026-03-04 | $2.33M derived: sum of 4 quarters · filed 2026-03-04 | |
| 2024-03-31 | $30.98M 10-Q · filed 2025-05-13 | $43.41M derived: sum of 2 quarters · filed 2026-03-04 | -$26.66M derived: sum of 3 quarters · filed 2026-03-04 | -$12.66M derived: sum of 4 quarters · filed 2026-03-04 | |
| 2023-12-31 | $12.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$57.64M derived: sum of 2 quarters · filed 2026-03-04 | -$43.64M derived: sum of 3 quarters · filed 2026-03-04 | -$44.45M 10-K · filed 2026-03-04 | |
| 2023-09-30 | -$70.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$56.08M derived: sum of 2 quarters · filed 2024-11-06 | -$56.88M 10-Q · filed 2024-11-06 | -$43.86M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2023-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.20M 10-Q · filed 2024-08-08 | $26.22M derived: sum of 3 quarters · filed 2025-03-20 | $30.87M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2023-03-31 | -$804.00K 10-Q · filed 2024-05-09 | $12.22M derived: sum of 2 quarters · filed 2025-03-20 | $16.87M derived: sum of 3 quarters · filed 2025-03-20 | $46.12M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2022-12-31 | $13.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $17.67M derived: sum of 2 quarters · filed 2025-03-20 | $46.92M derived: sum of 3 quarters · filed 2025-03-20 | $66.19M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $33.90M derived: sum of 2 quarters · filed 2023-11-08 | $53.16M 10-Q · filed 2023-11-08 | $53.23M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $29.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $48.51M 10-Q · filed 2023-08-08 | $48.58M derived: sum of 3 quarters · filed 2024-03-14 | $58.58M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $19.26M 10-Q · filed 2023-05-09 | $19.33M derived: sum of 2 quarters · filed 2024-03-14 | $29.33M derived: sum of 3 quarters · filed 2024-03-14 | $31.72M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.07M derived: sum of 2 quarters · filed 2024-03-14 | $12.46M derived: sum of 3 quarters · filed 2024-03-14 | $87.00K 10-K · filed 2024-03-14 | |
| 2021-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $12.39M derived: sum of 2 quarters · filed 2022-11-03 | $21.00K 10-Q · filed 2022-11-03 | -$79.36M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2021-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$9.98M 10-Q · filed 2022-08-08 | -$89.36M derived: sum of 3 quarters · filed 2023-03-14 | -$89.36M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2021-03-31 | -$12.37M 10-Q · filed 2022-05-09 | -$91.75M derived: sum of 2 quarters · filed 2023-03-14 | -$91.76M derived: sum of 3 quarters · filed 2023-03-14 | -$91.78M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2020-12-31 | -$79.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$79.39M derived: sum of 2 quarters · filed 2023-03-14 | -$79.41M derived: sum of 3 quarters · filed 2023-03-14 | -$47.36M 10-K · filed 2023-03-14 | |
| 2020-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$33.00K derived: sum of 2 quarters · filed 2021-11-04 | $32.02M 10-Q · filed 2021-11-04 | $57.14M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2020-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $32.02M 10-Q · filed 2021-08-02 | $57.15M derived: sum of 3 quarters · filed 2022-03-28 | $74.74M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2020-03-31 | $32.05M 10-Q · filed 2021-05-11 | $57.18M derived: sum of 2 quarters · filed 2022-03-28 | $74.77M derived: sum of 3 quarters · filed 2022-03-28 | $121.30M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2019-12-31 | $25.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $42.72M derived: sum of 2 quarters · filed 2022-03-28 | $89.25M derived: sum of 3 quarters · filed 2022-03-28 | $89.61M 10-K · filed 2022-03-28 | |
| 2019-09-30 | $17.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $64.12M derived: sum of 2 quarters · filed 2020-11-09 | $64.49M 10-Q · filed 2020-11-09 | -$62.32M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-06-30 | $46.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $46.89M 10-Q · filed 2020-08-10 | -$79.91M derived: sum of 3 quarters · filed 2021-03-18 | -$95.39M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-03-31 | $363.00K 10-Q · filed 2020-05-07 | -$126.44M derived: sum of 2 quarters · filed 2021-03-18 | -$141.92M derived: sum of 3 quarters · filed 2021-03-18 | -$142.45M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2018-12-31 | -$126.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$142.28M derived: sum of 2 quarters · filed 2021-03-18 | -$142.81M derived: sum of 3 quarters · filed 2021-03-18 | -$138.38M 10-K · filed 2021-03-18 | |
| 2018-09-30 | -$15.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$16.01M derived: sum of 2 quarters · filed 2019-10-30 | -$11.57M 10-Q · filed 2019-10-30 | -$7.07M derived: sum of 4 quarters · filed 2020-03-11 | |
| 2018-06-30 | -$530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.90M 10-Q · filed 2019-08-01 | $8.41M derived: sum of 3 quarters · filed 2020-03-11 | $29.74M derived: sum of 4 quarters · filed 2020-03-11 | |
| 2018-03-31 | $4.43M 10-Q · filed 2019-05-09 | $8.94M derived: sum of 2 quarters · filed 2020-03-11 | $30.27M derived: sum of 3 quarters · filed 2020-03-11 | $44.29M derived: sum of 4 quarters · filed 2020-03-11 | |
| 2017-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $25.83M derived: sum of 2 quarters · filed 2020-03-11 | $39.86M derived: sum of 3 quarters · filed 2020-03-11 | $43.95M 10-K · filed 2020-03-11 | |
| 2017-09-30 | $21.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $35.35M derived: sum of 2 quarters · filed 2018-11-07 | $39.44M 10-Q · filed 2018-11-07 | $40.43M derived: sum of 4 quarters · filed 2019-03-12 | |
| 2017-06-30 | $14.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $18.12M 10-Q · filed 2018-08-08 | $19.11M derived: sum of 3 quarters · filed 2019-03-12 | $22.83M derived: sum of 4 quarters · filed 2019-03-12 | |
| 2017-03-31 | $4.10M 10-Q · filed 2018-05-03 | $5.08M derived: sum of 2 quarters · filed 2019-03-12 | $8.81M derived: sum of 3 quarters · filed 2019-03-12 | ||
| 2016-12-31 | $986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $4.71M derived: sum of 2 quarters · filed 2019-03-12 | $36.93M 10-K · filed 2019-03-12 | $36.97M 10-K · filed 2018-03-13 | |
| 2016-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $35.94M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $32.21M 10-Q · filed 2017-08-08 | ||||
| 2015-12-31 | -$27.06M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |